Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Revenio Group Oyj
  6. News
  7. Summary
    REG1V   FI0009010912

REVENIO GROUP OYJ

(REG1V)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Revenio Group Corporation: Revenio updates its financial guidance for 2021

08/04/2021 | 01:11pm EDT

Revenio Group Corporation, Stock Exchange Release, August 4, 2021 at 20.10

Revenio updates its financial guidance for the year 2021

Revenio Group’s exchange rate adjusted net sales are estimated to grow very strongly from the previous year and profitability is to remain at a good level without non-recurring items. COVID-19 pandemic continues to cause uncertainty related to the markets.

Previous earnings guidance published on April 23, 2021:

COVID-19 pandemic continues to cause uncertainty related to the markets. Revenio Group’s exchange rate adjusted net sales are estimated to grow strongly from the previous year and profitability is to remain at a good level without non-recurring items.

Revenio Group Corporation
Board of Directors

For further information, please contact:

CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi

Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief
Revenio is a leading company in ophthalmological devices and software solutions. Revenio Group’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, the Group’s eye care software platform Oculo brings together clinical communication, telehealth, remote patient monitoring, and data analytics capabilities.

Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy and Oscare Medical Oy.

In 2020, the Group’s net sales totaled EUR 61.1 million and its operating profit amounted to EUR 17.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

© Modular Finance, source Nordic Press Releases

All news about REVENIO GROUP OYJ
09/20REVENIO OYJ : Group Corporation - Managers' Transactions
AQ
08/05REVENIO GROUP CORPORATION : Half-year financial report 1 January-30 June 2021
AQ
08/05Revenio Group Oyj Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/04REVENIO GROUP CORPORATION : Revenio updates its financial guidance for 2021
AQ
08/04Revenio Group Corporation Reaffirms Earnings Guidance for the Full Year 2021
CI
07/27REVENIO GROUP CORPORATION : Invitation to Revenio's audiocast and teleconference in relati..
AQ
06/18REVENIO GROUP CORPORATION : Hanna Vuornos appointed Director, People&Culture and as a memb..
AQ
06/18Revenio Group Corporation Appoints Hanna Vuornos as Director, People&Culture and as a M..
CI
06/15REVENIO GROUP CORPORATION : Increased number of shares entered into trade register
AQ
05/28REVENIO GROUP CORPORATION : Transfer of the Company's own shares
AQ
More news
Financials
Sales 2021 78,0 M 91,4 M 91,4 M
Net income 2021 17,3 M 20,2 M 20,2 M
Net Debt 2021 2,45 M 2,87 M 2,87 M
P/E ratio 2021 88,0x
Yield 2021 0,61%
Capitalization 1 515 M 1 775 M 1 776 M
EV / Sales 2021 19,5x
EV / Sales 2022 16,2x
Nbr of Employees 167
Free-Float 86,2%
Chart REVENIO GROUP OYJ
Duration : Period :
Revenio Group Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVENIO GROUP OYJ
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 57,05 €
Average target price 62,87 €
Spread / Average Target 10,2%
EPS Revisions
Managers and Directors
Jouni Erik Toijala President & Chief Executive Officer
Robin Allan Pulkkinen Chief Financial Officer
Pekka Veikko Juhani R÷nkń Chairman
Mika Salkola Director-Research & Development
Ari Isomńki Operations Director
Sector and Competitors
1st jan.Capi. (M$)
REVENIO GROUP OYJ13.42%1 775
SARTORIUS AG88.12%48 966
BIOTAGE AB (PUBL)82.59%1 910
CELLAVISION AB (PUBL)39.09%1 176
VAREX IMAGING CORPORATION66.79%1 097
ANGLE PLC148.17%380